Education
About Us
Working with TipRanks
Follow Us
ImmunoPrecise Antibodies (IPA)
NASDAQ:IPA
Earnings Data
Report Date
Sep 11, 2025TBA (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
―Last Year’s EPS
-0.11Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call highlighted strong performance in the fourth quarter with record revenues, significant margin improvements, and strategic partnerships driving growth in key segments, particularly BioStrand. The company's Canadian business also showed impressive growth. However, the overall fiscal year revenue growth was modest, and the divestiture of the Dutch subsidiary is taking longer than initially expected. Despite these challenges, the overall sentiment remains positive due to the company's achievements and strategic focus.Company Guidance
Record-Setting Fourth Quarter Revenue
The company achieved $7 million in revenue for the fourth quarter, marking the highest quarterly revenue in its history. This represents an 8.1% increase over the year-ago quarter and a 13.5% increase from the prior quarter.
Significant Gross Margin Improvement
Gross margin improved to 64% in the fourth quarter, up from 48% in the same quarter last year. For the full fiscal year, gross margins expanded by 600 basis points from 49% to 55%.
BioStrand Segment Growth
The BioStrand segment grew more than 180% year-over-year, delivering gross margins approaching 90%. It is expected to remain a strong contributor to top-line performance and support continued margin expansion.
Record Adjusted EBITDA Performance
The company narrowed its adjusted EBITDA loss to $316,000, a significant improvement from a $1.7 million loss in the same quarter last year, highlighting improved operational efficiency.
Strong Growth in Canadian Business
Canadian sales orders reached $4.3 million in the fourth quarter, more than double historical quarters, with year-over-year sales in Canada increasing by 47% and quarterly orders up 83%.
Strategic Collaborations and Partnerships
Notable collaborations include partnerships with RIBOPRO, Vultr, and a multibillion-dollar technology company, as well as advancements in AI infrastructure and drug discovery platforms.
NASDAQ Compliance and Leadership Strengthening
The company regained compliance with NASDAQ's minimum bid price requirement, reflecting market confidence, and strengthened its leadership team with new appointments.
IPA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
IPA Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Jul 29, 2025 | $2.02 | $1.72 | -14.85% |
Mar 28, 2025 | $0.44 | $0.39 | -11.36% |
Dec 10, 2024 | $0.42 | $0.40 | -4.76% |
Sep 16, 2024 | $0.67 | $0.54 | -19.40% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does ImmunoPrecise Antibodies (IPA) report earnings?
ImmunoPrecise Antibodies (IPA) is schdueled to report earning on Sep 11, 2025, TBA (Confirmed).
What is ImmunoPrecise Antibodies (IPA) earnings time?
ImmunoPrecise Antibodies (IPA) earnings time is at Sep 11, 2025, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is IPA EPS forecast?
Currently, no data Available